Business Context and Reporting Period
This Form 8-K filing by Arvinas, Inc. (ARVN) was submitted on November 20, 2019. The report details a corporate governance event: the election of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Laurie Smaldone Alsup, M.D., as a Class I director, effective November 20, 2019. Dr. Alsup was also appointed to the Compensation Committee, which now consists of Dr. Alsup, Liam Ratcliffe, M.D., Ph.D., and Timothy Shannon, M.D. (Chair).
Compensation and Equity Grant Details
- Cash Compensation: Dr. Alsup will receive an annual cash retainer of $35,000 for board service and an additional $5,000 for serving on the Compensation Committee.
- Equity Grant: Dr. Alsup was granted a stock option to purchase 25,846 shares of common stock.
- Exercise Price: The per-share exercise price is $34.07, based on the closing price on the grant date.
- Vesting Schedule: The option vests monthly in equal amounts over a three-year period, contingent on continued service.
- Expenses: The company will reimburse reasonable travel and other expenses related to board and committee meetings.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on business outlook, specific risks, contingencies, or unusual items beyond the standard vesting conditions tied to continued service.
Key Facts for Investor Verification
- Confirmation of Dr. Alsup's tenure on the Board and Compensation Committee.
- The total equity dilution impact of the 25,846 share option grant.
- The specific vesting schedule and conditions attached to the new director's equity.
- Any potential conflicts of interest or additional compensation arrangements not detailed in this summary.